JPS60222424A - インタ−ロイキン−２組成物 - Google Patents
インタ−ロイキン−２組成物Info
- Publication number
- JPS60222424A JPS60222424A JP60013226A JP1322685A JPS60222424A JP S60222424 A JPS60222424 A JP S60222424A JP 60013226 A JP60013226 A JP 60013226A JP 1322685 A JP1322685 A JP 1322685A JP S60222424 A JPS60222424 A JP S60222424A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- freeze
- aqueous solution
- solution
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010002350 Interleukin-2 Proteins 0.000 title claims abstract description 56
- 102000000588 Interleukin-2 Human genes 0.000 title claims abstract description 56
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 102000008100 Human Serum Albumin Human genes 0.000 claims abstract description 6
- 108091006905 Human Serum Albumin Proteins 0.000 claims abstract description 6
- -1 aliphatic amino acid Chemical class 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 abstract description 33
- 239000000243 solution Substances 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 15
- 150000001413 amino acids Chemical class 0.000 abstract description 9
- 238000002347 injection Methods 0.000 abstract description 8
- 239000007924 injection Substances 0.000 abstract description 8
- 238000004108 freeze drying Methods 0.000 abstract description 7
- 150000002772 monosaccharides Chemical class 0.000 abstract description 7
- 238000007710 freezing Methods 0.000 abstract description 5
- 230000008014 freezing Effects 0.000 abstract description 5
- 238000013329 compounding Methods 0.000 abstract description 4
- 238000003860 storage Methods 0.000 abstract description 4
- 239000000047 product Substances 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 235000002639 sodium chloride Nutrition 0.000 description 8
- 150000005846 sugar alcohols Chemical class 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 102000055277 human IL2 Human genes 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- 229910052722 tritium Inorganic materials 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012156 elution solvent Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- VZZUJVDCIBINIT-YDALLXLXSA-N (2s)-2-acetamido-3-(1h-indol-3-yl)propanoic acid;sodium Chemical compound [Na].C1=CC=C2C(C[C@H](NC(=O)C)C(O)=O)=CNC2=C1 VZZUJVDCIBINIT-YDALLXLXSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- GGZZISOUXJHYOY-UHFFFAOYSA-N 8-amino-4-hydroxynaphthalene-2-sulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=C2C(N)=CC=CC2=C1O GGZZISOUXJHYOY-UHFFFAOYSA-N 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000010981 drying operation Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910052739 hydrogen Chemical group 0.000 description 1
- 239000001257 hydrogen Chemical group 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 108090000237 interleukin-24 Proteins 0.000 description 1
- 102000003898 interleukin-24 Human genes 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229960005480 sodium caprylate Drugs 0.000 description 1
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60013226A JPS60222424A (ja) | 1985-01-25 | 1985-01-25 | インタ−ロイキン−２組成物 |
| EP19850302176 EP0158487B1 (en) | 1984-04-09 | 1985-03-28 | Stable composition of interleukin-2 |
| DE8585302176T DE3583880D1 (de) | 1984-04-09 | 1985-03-28 | Stabile interleukin-2-zusammensetzung. |
| AT85302176T ATE66612T1 (de) | 1984-04-09 | 1985-03-28 | Stabile interleukin-2-zusammensetzung. |
| PH32069A PH22897A (en) | 1984-04-09 | 1985-03-29 | Stable composition of interleukin-2 |
| CN85101301A CN1019453B (zh) | 1985-01-25 | 1985-04-01 | 白细胞介素-2的稳定组合物的制备方法 |
| DK148885A DK148885A (da) | 1984-04-09 | 1985-04-02 | Stabilt praeparat af interleukin-2 |
| CA000478351A CA1285478C (en) | 1984-04-09 | 1985-04-04 | Stable composition of interleukin-2 |
| NZ211702A NZ211702A (en) | 1984-04-09 | 1985-04-04 | Interleukin composition |
| IL74823A IL74823A (en) | 1984-04-09 | 1985-04-04 | Stable composition of interleukin-2 |
| AU40839/85A AU579359B2 (en) | 1984-04-09 | 1985-04-04 | Stable composition of interleukin-2 |
| KR1019850002345A KR920005048B1 (ko) | 1984-04-09 | 1985-04-08 | 인터로이킨-2의 안정화 조성물 제조방법 |
| US06/720,754 US4645830A (en) | 1984-04-09 | 1985-04-08 | Stable composition of interleukin-2 and albumin |
| PT80247A PT80247B (pt) | 1984-04-09 | 1985-04-08 | Processo para a preparacao de uma composicao de interleucina-2 estavel |
| ES542028A ES8603271A1 (es) | 1984-04-09 | 1985-04-08 | Un metodo de producir una composicion de interleuquina-2 |
| IE90285A IE58161B1 (en) | 1984-04-09 | 1985-04-10 | Stable composition of interleukin-2 |
| US06/931,704 US4812557A (en) | 1984-04-09 | 1986-11-17 | Stable composition of interleukin-2 and human serum albumin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60013226A JPS60222424A (ja) | 1985-01-25 | 1985-01-25 | インタ−ロイキン−２組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59071568A Division JPS60215631A (ja) | 1984-04-09 | 1984-04-09 | インタ−ロイキン−２組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60222424A true JPS60222424A (ja) | 1985-11-07 |
| JPH0378847B2 JPH0378847B2 (https=) | 1991-12-17 |
Family
ID=11827263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60013226A Granted JPS60222424A (ja) | 1984-04-09 | 1985-01-25 | インタ−ロイキン−２組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS60222424A (https=) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62164631A (ja) * | 1986-01-07 | 1987-07-21 | 塩野義製薬株式会社 | インタ−ロイキン−２組成物 |
| JPS6322523A (ja) * | 1986-06-28 | 1988-01-30 | ビオテスト フアルマ ゲゼルシヤフト ミツト ベシユレンクタ− ハフツング | ヒトおよび動物の治療に用いられるインタ−ロイキン２製剤の安定化方法ならびにこの製剤を含む安定化水溶液または固体 |
| JPS63152326A (ja) * | 1986-07-18 | 1988-06-24 | Chugai Pharmaceut Co Ltd | 安定な顆粒球コロニ−刺激因子含有製剤 |
| JPS6485920A (https=) * | 1986-12-04 | 1989-03-30 | Takeda Chemical Industries Ltd |
-
1985
- 1985-01-25 JP JP60013226A patent/JPS60222424A/ja active Granted
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62164631A (ja) * | 1986-01-07 | 1987-07-21 | 塩野義製薬株式会社 | インタ−ロイキン−２組成物 |
| JPS6322523A (ja) * | 1986-06-28 | 1988-01-30 | ビオテスト フアルマ ゲゼルシヤフト ミツト ベシユレンクタ− ハフツング | ヒトおよび動物の治療に用いられるインタ−ロイキン２製剤の安定化方法ならびにこの製剤を含む安定化水溶液または固体 |
| JPS63152326A (ja) * | 1986-07-18 | 1988-06-24 | Chugai Pharmaceut Co Ltd | 安定な顆粒球コロニ−刺激因子含有製剤 |
| JPS6485920A (https=) * | 1986-12-04 | 1989-03-30 | Takeda Chemical Industries Ltd |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0378847B2 (https=) | 1991-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0158487B1 (en) | Stable composition of interleukin-2 | |
| AU2020401160B2 (en) | Pharmaceutical TACI-Fc fusion protein formulation | |
| CN118203658A (zh) | 一种重组抗Claudin18.2全人源单克隆抗体注射液制剂及制备方法 | |
| JP4617058B2 (ja) | コンセンサスインターフェロンのＢ型肝炎表面抗原とｅ抗原の抑制剤としての応用 | |
| DK158677B (da) | Insulinderivater og anvendelsen deraf, injicerbar oploesning indeholdende insulinderivaterne samt fremgangsmaade til fremstilling af oploesningen. | |
| EP3639845B1 (en) | Il-15 protein complex pharmaceutical composition and uses thereof | |
| EA027325B1 (ru) | Составы этанерцепта, стабилизированные ксилитом | |
| EP0344796A2 (en) | Crystalline human granulocyte colony stimulating factor and process for preparing the same | |
| EP4059512A1 (en) | Aqueous pharmaceutical composition containing fusion protein of serum albumin and growth hormone | |
| EP0168008A2 (en) | Stable composition of gamma-interferon | |
| EP0446582A1 (en) | Method for producing of recombinant human cysteineless gamma-interferon free of methionine at n-terminal | |
| US20080260684A1 (en) | Method for the Purification of G-Csf | |
| JPS60222424A (ja) | インタ−ロイキン−２組成物 | |
| IE61444B1 (en) | Process for preparing and purifying interferon | |
| JPH0361652B2 (https=) | ||
| JPS61197527A (ja) | インタ−ロイキン−２組成物 | |
| KR101868966B1 (ko) | 열 안정성을 증진시킨 사람 상피세포 성장인자의 조성물 | |
| EP0408146A2 (en) | Method for the purification of therapeutically active recombinant acidic fibroblast growth factor | |
| JPWO1992014832A1 (ja) | ヒトｂｃｄｆの精製法 | |
| JPS63185997A (ja) | 生理活性ポリペプチド、その製法及び用途 | |
| JP2589094B2 (ja) | 抗悪性腫瘍剤 | |
| JP2006508695A (ja) | 単量体インスリン | |
| HK40077299A (en) | Pharmaceutical taci-fc fusion protein formulation | |
| JPS6144826A (ja) | γ型インタ−フエロン組成物 | |
| HK40077299B (en) | Pharmaceutical taci-fc fusion protein formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |